Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 81 publications.
Skip to main content
Brockbank J, Hancock H, Khare A, Joshi P, Risson V. Cost-effectiveness of [177Lu]Lu-PSMA-617 in progressive PSMA-positive metastatic castration-resistant prostate cancer. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S121. doi: 10.1016/j.jval.2024.10.619
Adelakun A, Dolph M, Matthews E, Oglebsy A, Campbell K, Davis A, Xu J, Hardy I, Danchenko N, Anderson SJ. Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada. Poster presented at the HIV Drug Therapy Glasgow 2024; November 10, 2024. Glasgow, Scotland. [abstract] J Int AIDS Soc. 2024 Nov; 27:234-5.
Yousif Z, Nangia A, Abeysinghe S, Jiang J, Sanchirico M, Fan T. Comparative efficacy of biologics for the induction of clinical remission and response in biologic-naïve patients with moderate-to-severe crohn's disease: outcomes from frequentist and bayesian network meta-analyses. Poster presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024; October 29, 2024. Philadelphia, PA.
O'Brien P, Campbell K, Anderson SJ, Cornic L, Davis A, Schroeder M. Cost-effectiveness of every two month Cabotegravir Long-Acting (CAB-LA) for Pre-exposure Prophylaxis (PrEP) compared with daily oral Tenofovir Disoproxil Fumarate (TDF)/ emtricitabine (FTC) as PrEP to prevent HIV-1 UK. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S109. doi: 10.1016/j.jval.2024.03.580
Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772
Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S119. doi: 10.1016/j.jval.2023.09.772
Morris MJ, Armstrong AJ, Chi K, de Bono J, Herrmann K, Krause B, Rahbar K, Sartor O, Tagawa ST, Nagarajah J, Wei XX, Nordquist LT, Koshkin VS, Saad F, Vickers A, Ghouse R, Wu J, Mirante O, Fizazi K. Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer. Poster presented at the ESMO Congress 2023; October 22, 2023. Madrid, Spain.
Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, Kurosky S, Gessner BD, Begier E. Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries. Open Forum Infect Dis. 2023 Oct 20;10(11):ofad513. doi: 10.1093/ofid/ofad513
Fan Q, Hawe E, Yang J, Burgess B, Bullano M, Mokdad A. Cost outcomes of noninhibitor patients with hemophilia A switching from prophylaxis with factor VIII to emicizumab: a meta-analysis of real-world evidence studies in the United States. Poster presented at the AMCP Nexus 2023; October 16, 2023. Orlando, FL. [abstract] J Manag Care Pharm. 2023 Oct; 29(10-a Suppl):S35.
Nangia A, Simou E, Abeysinghe S, Colosia A, Bektas M, Workman J, Gao S, Bello N. Incidence rate of infections and association between lupus nephritis and serious infections in patients with systemic lupus erythematosus: systematic literature review and meta-analyses. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S180. doi: 10.1016/j.jval.2023.03.972
Yousif Z, Schultz BG, Candela N, Harold S, Bell J, Turpin R, Hartley L. Systematic literature review to evaluate randomized clinical trials of advanced therapies for moderate to severe crohn's disease. Poster presented at the ISPOR 2023 Conference; May 6, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S15. doi: 10.1016/j.jval.2023.03.085
Bello N, Meyers KJ, Workman J, Hartley L, McMahon M. Cardiovascular events and risk in patients with systemic lupus erythematosus: systematic literature review and meta-analysis. Lupus. 2023 Mar;32(3):325-41. doi: 10.1177/09612033221147471
Bello N, Meyers KJ, Workman J, Marcano Belisario J, Cervera R. Systematic literature review and meta-analysis of venous thromboembolism events in systemic lupus erythematosus. Rheum Ther. 2023 Feb 1;10(1):7-34. doi: 10.1007/s40744-022-00513-1
Ainsworth C, Higuchi K, Simou E, Guyot P, Araujo L, Greene N. Relative differences in brain volume loss with teriflunomide vs other disease-modifying therapies in relapsing multiple sclerosis: a systematic review and network meta-analysis. Poster presented at the AMCP Nexus 2022; October 11, 2022. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2022 Oct; 28(10-a):S73-4. Previously presented at the ACTRIMS Forum 2022.
Whalley D, Belongie K, Frangiosa T, Krasa H, Mladsi DM, Twiss J, Wolowacz S. Understanding the patient experience of erythropoietic protoporphyria and x-linked protoporphyria: a qualitative study. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Petrillo Billet J. Driving outcomes in mild cognitive impairment/Alzheimer's disease - a review of association between driving simulator measures and clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Billet JP. Impact of Huntington's disease on driving: a review of driving simulator measures and association with clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Layton JB, Forns J, Turner ME, Dempsey C, Bartsch JL, Anthony MS, Danysh HE, Ritchey ME, Demos G. Falls and fractures in patients with Parkinson's Disease–related psychosis treated with Pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes. 2022 Mar;9(1):9-22. doi: 10.1007/s40801-021-00284-1
Ainsworth C, Higuchi K, Simou E, Guyot P, Greene N. Relative differences in brain volume loss with teriflunomide versus other disease-modifying therapies in relapsing multiple sclerosis: a systematic review and network meta-analysis. Poster presented at the ACTRIMS Forum 2022; February 24, 2022. West Palm Beach, FL.
Zhou X, Davenport E, Ouyang J, Hoke ME, Garbinsky D, Agarwal I, Krasa HB, Oberdhan D. Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD. Kidney Int Rep. 2022 Feb 19;7(5):1037-48. doi: 10.1016/j.ekir.2022.02.009
Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS One. 2021 Jan 27. doi: 10.1371/journal.pone.0246121
Njue A, Coyne C, Margulis AV, Wang D, Marks MA, Russell K, Das R, Sinha A. The role of congenital cytomegalovirus infection in adverse birth outcomes: a review of the potential mechanisms. Viruses. 2020 Dec 24;13(1):E20. doi: 10.3390/v13010020
Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Zhou X, Garbinsky D, Ouyang J, Davenport E, Agarwal I, Oberdhan D. Longitudinal data on treatment duration and compliance from autosomal dominant polycystic kidney disease clinical trials with tolvaptan. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa139.S. doi: 10.1093/ndt/gfaa139.SO093
Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across an expanded pooled database of multiple autosomal dominant polycystic kidney disease clinical studies. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa142.P. doi: 10.1093/ndt/gfaa142.P0037
Zhou X, Davenport EK, Ouyang J, Krasa H, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across a pooled database of multiple Autosomal Dominant Polycystic Kidney Disease (ADPKD) clinical studies. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):663.
Cawson M, Wolowacz S, Doward L, Sinha A. Health utility estimates for congenital cytomegalovirus disease: conceptual design considerations. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Njue A, Margulis AV, Lyall M, Nuabor W, Marks M, Russell K, Sinha A. Congenital cytomegalovirus: what are the rates of maternal screening, diagnostic amniocentesis, and elective termination? Poster presented at the ID Week 2019; October 4, 2019. Washington, DC.
Vickers AD, Winfree KB, Cuyun Carter G, Kiiskinen U, Jen MH, Stull D, Kaye JA, Carbone DP. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis. BMC Cancer. 2019 Apr 15;19(1):353. doi: 10.1186/s12885-019-5569-5.
Nance R, Vannappagari V, Johannes C, Calingaert B, Saltus C, Boswell S, Rodriguez B, Moore R, Eron J, Geng E, Mathews WC, Saag MS, Kitahata M, Delaney JAC, Crane HM, Centers For AIDS Research Network of Integrated Clinical Systems (CNICS). Viral failure among persons living with HIV initiating dolutegravir-based vs. other recommended regimens in real-world clinical care settings. Poster presented at the IDWeek 2017 Conference; October 2017. San Diego, CA. [abstract] Open Forum Infect Dis. 2017 Oct 4; 4((Suppl 1)):S39. doi: 10.1093/ofid/ofx162.095
Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. Curr Med Res Opin. 2017 Aug;33(8):1457-66. doi: 10.1080/03007995.2017.1325730
Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Efficacy of palbociclib combinations versus endocrine therapies in advanced/ metastatic breast cancer: network meta-analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A710.
Colosia A, Khan S, Hackshaw MD, Oglesby A, Kaye JA, Skolnik JM. A systematic literature review of adverse events associated with systemic treatments used in advanced soft tissue sarcoma. Sarcoma. 2016 Jul 19;2016:3597609. doi: 10.1155/2016/3597609
Pladevall M, Riera Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S. Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies. BMC Cardiovasc Disord. 2016 Jan 15;16(1):14. doi: 10.1186/s12872-016-0187-5
Graham CN, McBride D, Miles L, Kneidl J, Mollon P. Estimation of indirect (work-related productivity) costs associated with moderate-to-severe plaque psoriasis in Germany. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Klimes J, Mollon P, Graham C, Rajnoch J, Dostal F, Skalicky D, Jordan P, Depta J. Cost-effectiveness analysis of secukinumab compared to ustekinumab in the treatment of moderate to severe plaque psoriasis in the Czech Republic. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
D'Ausilio A, Aiello A, Daniel F, Graham C, Roccia A, Toumi M. A cost-effectiveness analysis of secukinumab 300 mg vs current therapies for the treatment of moderate to severe plaque psoriasis in Italy. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Bateman ED, Esser D, Chirila C, Fernandez M, Fowler A, Moroni-Zentgraf P, FitzGerald JM. Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: systematic review and network meta-analysis. J Allergy Clin Immunol. 2015 Oct;136(4):914-22. doi: 10.1016/j.jaci.2015.03.023
Graham CN, Mollon P, Miles L, McBride D. A new cost-effectiveness framework for modeling psoriasis treatment. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Vickers AD, Mody R, Bergman A, Ling CS, Ainsworth C, Medjedovic J, Smyth M. Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): a systematic review and network meta-analysis. Poster presented at the 2015 Digestive Disease Week; May 2015. Washington, DC. [abstract] Gastroenterology. 2015 Apr 16; 148(4, Suppl 1):S272. Previously presented at the 10th Congress of the European Crohn's and Colitis Organization.
Vickers AD, Mody RR, Bergman A, Ling CS, Ainsworth C, Medjedovic J, Smyth M. Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): a systematic review and network meta-analysis. Poster presented at the 10th Congress of the European Crohn's and Colitis Organization; February 18, 2015. Barcelona, Spain. [abstract] J Crohns Colitis. 2015 Feb 2; 9(Suppl 1):S357-8. doi: 10.1093/ecco-jcc/jju027.672
Rosseli D, Rueda J, Wolowacz SE, Brockbank JA, Abeysinghe SS. Cost-effectiveness of dabigatran compared with warfarin, apixaban, rivaroxaban and low molecular weight heparins for the treatment and secondary prevention of venous thromboembolism in Colombia. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.
Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, Viswanathan M, Perez-Gutthann S. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014 Oct 10;6:359-68. doi: 10.2147/CLEP.S66677
Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, Romio S, Perez-Gutthann S. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord. 2014 Sep 26;14(1):129. doi: 10.1186/1471-2261-14-129
Odom DM, Chirila C, Sherrill EH, Wang J, Sherif BN. Practical issues when conducting network meta-analyses with a limited number of studies. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring utility for economic models within clinical trials: can we do better? Presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.
Ainsworth C, Kiri S, Ling CS, Heyes AE, Hass B. The global burden, incidence, and prevalence of chronic hepatitis c. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A342.
Riera Guardia N, Margulis AV, Pladevall-Vila M, Varas-Lorenzo C, Perez-Gutthann S. Methods issues in observational studies of the cardiovascular risk associated with glucose-lowering medications: results of a systematic review and evaluation. Poster presented at the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; October 7, 2013. [abstract] Pharmacoepidemiol Drug Saf. 22(Suppl 1):S80-81.
Margulis AV, Pladevall-Vila M, Riera Guardia N, Varas-Lorenzo C, Hazell L, Perez-Gutthann S. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastele-Ottawa Scale and the RTI Item Bank. Poster presented at the 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 2013.
Varas-Lorenzo C, Riera Guardia N, Castellsague J, Arfe A, Perez-Gutthann S. The SOS project: risk of heart failure and use of nonsteroidal anti-inflammatory drugs. A meta-analysis of observational studies. Poster presented at the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. [abstract] Pharmacoepidemiol Drug Saf. 22(S1):67.